Top Tech Companies (124)
Don't see your company?
Create a company profile
Atlas Biomed is a personalized health company applying the latest genetic technologies to inspire consumers into a positive lifestyle change, and lead them into a healthier future.
Pangea develops transformative medicines for neurological disorders, deploying AI to uncover promising molecules from natural sources with prior evidence of efficacy and tolerability in humans based on traditional use
Causaly amplifies human cognitive abilities to expand the boundaries of discovery towards making the best decisions in Biomedicine. To achieve this, we are teaching computers to read all knowledge ever published and develop an interface that allows humans to answer questions they can’t ask anywhere else.
Tailor Bio is developing an AI-driven drug discovery platform for pan-cancer precision medicine. We're doing this by focussing on Chromosomal Instability, a genomic phenomenon present in 80% of all cancers.
Enara Bio is shining a light on Dark Antigen® and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients. Our pioneering EDAPT® platform enables us to discover novel cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing database of Dark Antigens that can address the unmet need for cancer-specific targets that are homogenously expressed and highly prevalent in solid tumors. We are advancing multiple approaches to exploit these Dark Antigen targets, with an internal focus on TCR-directed immunotherapies, and additional therapeutic partnerships with Boehringer Ingelheim and another undisclosed global pharmaceutical company. Based in Oxford, UK, Enara Bio is backed by RA Capital, Samsara Biocapital and SV Health Investors. For more information, please visit: www.enarabio.com Comments and DMs to this account are not monitored, for any further information please head to our website
Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients’ quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant patients. Pulmocide’s innovative approach to drug development provides a novel potential therapy that has been specifically designed to treat the most common fungal lung disease, pulmonary aspergillosis. Opelconazole was designed for inhaled delivery to minimize systemic exposure and deliver a high concentration of drug with a long retention time at the site of infection. This approach could improve treatment outcomes in patients with fungal lung disease without increasing systemic side effects and without interactions with other medications. The Pulmocide team is well experienced in the discovery and development of inhaled therapies for respiratory and infectious disease indications. They have particular expertise in the identification of novel compounds that can be delivered directly to the lungs.
Phytoform are making agriculture sustainable & unlocking the genetic potential of plants.
An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions. Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.
Shellworks is a design-led techbio company that creates uncompromising, compostable packaging solutions made from naturally-derived materials. Our first material is called Vivomer, a bio-based, vegan and home compostable alternative to plastic. Working in collaboration with nature, Vivomer is made and unmade by microbes
Personalised cancer therapeutics platform pioneered at Mount Sinai Medical Center
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases
FabricNano is a biotechnology company based in London. Our mission is to transform industrial chemical processes using cell-free biomanufacturing. Empowering users with the world’s most advanced, flexible and easily-scalable biocatalyst platform. We develop and sell biocatalysts for high volume industrial applications. Data-driven in our approach to enzyme and Immobilization Engineering™, we only use biocatalyst materials that can already be manufactured by the tonne. Our clients range from startups to international chemical clients like Sumitomo Chemical Company, all of which are looking for highly stable and performant biocatalysts to enable profitable production of sustainable and bio-based chemicals. The FabricNano offer starts with novel Immobilization Engineering™ for enzyme stabilization, followed by budget-conscious protein engineering and process engineering to reach the client’s targets for commercialization of the new biochemical production process.
Inoviv uses a novel technology platform based on targeted proteomics to support pharmaceutical companies with biomarker test development.
Baseimmune was founded in 2019 as a discovery phase start-up in the antigen discovery and vaccine development field
Let's transform lives together and work towards a functional, confident smile on every face
Ori Biotech is a London- and New Jersey-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalised, lifesaving treatments. By fully automating and standardising CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past
We believe that everyone - irrespective of who they are or where they live - deserve medications that work
We are an RNA delivery and therapeutics company. Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. Our Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improve the stability, safety, and transfection efficiency of RNA. We use sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and are maximizing the potential of our technology through research partnerships. Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, we have fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate
The way we see it, the impossible is not impossible. It’s simply what hasn’t been achieved yet. For more than 30 years, we’ve pursued it, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases. Creating Possible drives everything we do. It’s evident in our mission and core values. This is how we built a culture of excellence that is fueled by a passion for improving lives of people around the world. For us, nothing is impossible – because of the people we work with, the communities we stand with and the partners we push forward with. Our ~12,000 employees band together through science, grit, compassion and courage to prove the impossible wrong. At Gilead, the tangible results of your contributions are evident. Where every individual matters. Where all employees can enhance their skills through ongoing development. And where we start every day with one question: “What’s next?” Social Media Guidelines: https://gilead.inc/3t1m7d5
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
